A Phase 1, open-label, randomized, 3-way crossover study to evaluate the relative bioavailability of a single oral dose of aspirin administered as PA32540 (aspirin/omeprazole) or as the aspirin component of PA32540 or as Ecotrin 325 mg in healthy volunteers

Trial Profile

A Phase 1, open-label, randomized, 3-way crossover study to evaluate the relative bioavailability of a single oral dose of aspirin administered as PA32540 (aspirin/omeprazole) or as the aspirin component of PA32540 or as Ecotrin 325 mg in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2010

At a glance

  • Drugs Aspirin; Aspirin/omeprazole
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced gastrointestinal damage
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top